SCHEMBL3758325

SCHEMBL3758325

CCNC(=O)C1c2cc(Cl)ccc2C(=O)N1[C@H](C)c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 6/20 0.61
P2RX7 Q99572 3/20 0.45
KCNH2 Q12809 1/20 0.44
PTGES O14684 1/20 0.43
TSHR P16473 2/20 0.41
BRS3 P32247 1/20 0.41
HTT P42858 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
GPR139 Q6DWJ6 1/20 0.38
ALDH1A1 P00352 2/20 0.37
BRD4 O60885 1/20 0.37
LMNA P02545 1/20 0.36
THRB P10828 1/20 0.36
HPGD P15428 1/20 0.36
HSP90AA1 P07900 2/20 0.36
HSP90AB1 P08238 2/20 0.36
NR3C2 P08235 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3750444 0.90 KCNA5 (0.48) KCNA5P2RX7KCNH2PTGESTSHR
SCHEMBL3745315 0.90 KCNA5 (0.77) KCNA5P2RX7KCNH2PTGESBRS3
SCHEMBL3754228 0.90 KCNA5 (0.77) KCNA5P2RX7KCNH2PTGESBRS3
SCHEMBL3749096 0.88 KCNA5 (0.55) KCNA5P2RX7KCNH2PTGESTSHR
SCHEMBL3942591 0.86 KCNA5 (0.45) KCNA5P2RX7KCNH2PTGESTSHR
SCHEMBL3754303 0.85 KCNA5 (0.54) KCNA5P2RX7KCNH2PTGESTSHR
SCHEMBL3756579 0.85 KCNA5 (0.53) KCNA5P2RX7KCNH2PTGESTSHR
SCHEMBL3751700 0.85 KCNA5 (0.53) KCNA5P2RX7KCNH2PTGESTSHR
SCHEMBL3752066 0.83 KCNA5 (0.64) KCNA5P2RX7KCNH2TSHRBRS3
SCHEMBL3751379 0.82 KCNA5 (0.54) KCNA5P2RX7KCNH2PTGESTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias ASTRAZENECA AB (SE) 2010-11-25 US claimed
US-20080015237-A1 NEW COMPOUNDS I/418 ASTRAZENECA AB (SE) 2008-01-17 US claimed
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias ASTRAZENECA AB (SE) 2010-11-25 US disclosed
EP-2049484-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS AstraZeneca AB (SE) 2009-04-22 EP disclosed
WO-2008008022-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS ASTRAZENECA AB (SE) 2008-01-17 WO disclosed
US-20080015237-A1 NEW COMPOUNDS I/418 ASTRAZENECA AB (SE) 2008-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015237-A1 NEW COMPOUNDS I/418 KCNH1, KCNH2, KCNH3 KCNA5 69/4885P2RX7 1839/4885KCNH2 2/4885
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias KCNH1, KCNH2, KCNQ2 KCNA5 72/4885P2RX7 1138/4885KCNH2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.